| Methods |
Randomized, double‐blind, placebo‐controlled.
Weight loss trial. |
| Participants |
1507 patients. 41% hypertensive and 61% dyslipidemic. 1 year follow‐up. Mean age 45 y. Mean BMI 36.0 kg/m2. Mean weight 101 kg. Europe and US. |
| Interventions |
Rimonabant 20 mg daily (n=599). Attrition rate 39%.
Rimonabant 5 mg daily (n=603). Attrition rate 37%.
Placebo (n=305). Attrition rate 42%. |
| Outcomes |
weight loss, 5% and 10% responders, waist circ, lipid profile, glucose, insulin, blood pressure, insulin resistance |
| Notes |
Co‐interventions:600 kcal/d deficit diet and exercise counseling |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Low risk |
A ‐ Adequate |
